X

Drug Profile

Lamivudine/zidovudine

Alternative Names: Combivir; Lamuzid; Zidovudine/lamivudine

Latest Information Update: 05 Nov 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GlaxoSmithKline
Class Antiretrovirals; Azides; Dideoxynucleosides; Pyrimidine nucleosides; Small molecules
Mechanism of Action RNA-directed DNA polymerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed HIV infections

Most Recent Events

06 Dec 2007 The European Commission has approved lamivudine/zidovudine for use in children and infants
16 Jul 2001 A study has been added to the adverse events and Viral Infections therapeutic trials sections
23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com